Uppsala, Sweden – February 20, 2017 – Orexo AB (publ.) announces that it has successfully completed a limited bond buyback program and in total purchased Orexo corporate bonds in the market with a nominal value of MSEK 59. The program was initiated on February 8, 2017, and completed by February 17, 2017. After the purchase Orexo owns own bonds with a nominal value of MSEK 158.
Pareto Securities and Danske Bank assisted Orexo in this process.
For more information please contact:
|Orexo AB (publ.)|
|Henrik Juuel, EVP and CFO||Lena Wange, IR & Communications Manager|
|Tel: +46 (0)18 780 88 00||Tel: +46 (0)18 780 88 00|
|Email: email@example.com||Email: firstname.lastname@example.org|
Orexo is a specialty pharmaceutical company commercializing its proprietary product Zubsolv® for treatment of opioid dependence in the US. Zubsolv is an advanced formulation of buprenorphine and naloxone using Orexo’s unique knowledge and expertise in sublingual drug delivery. R&D is focusing on reformulation of known substances to new improved products that meet great unmet medical needs by using its patented proprietary technologies. Orexo’s share is listed on Nasdaq Stockholm Exchange Mid Cap (STO:ORX) and is available as ADRs on OTCQX (ORXOY) in the US. Orexo’s global headquarters and R&D are based in Uppsala, Sweden.